Table 1.
Characteristics of study participants
| HIV-Infected (n=500) | HIV-Uninfected (n=500) | p value | |
|---|---|---|---|
| Characteristic* | n (% or IQR) | n (% or IQR) | |
| Median Age, years | 38 (IQR 31–44) | 37 (IQR 32–44) | 0.0250 |
| Female | 334 (67) | 336 (67) | 0.893 |
| BMI >25 | 74 (15) | 122 (24) | <0.001 |
| On TB treatment | 10 (2) | 1 (0.2) | 0.006 |
| Current herb use | 10 (2) | 36 (7) | <0.001 |
| Current alcohol use | 112 (22) | 79 (16) | 0.008 |
| Heavy liquor use (≥1.25 L/week) | 12 (2) | 12 (2) | 0.651 |
| Lifetime occupational fishing | 5 (1) | 1 (0.2) | 0.101 |
| HBsAg positive | 23 (5) | 14(3) | 0.133 |
| Anti-HBc positive | 223 (45) | 155 (31) | <0.001 |
| Schistosoma antibody positive | 71 (14) | 46 (9) | 0.014 |
| Median ALT | 22 (IQR 16–31) | 19 (IQR 15–25) | <0.001 |
| Median AST | 27 (IQR 22–35) | 23 (IQR 20–27) | <0.001 |
| ACTG ALT hepatoxicity criteria(%) | |||
| No Elevation | 446 (89) | 472 (94) | 0.003 |
| Grade1 (1–2.5 X ULN) | 44 (9) | 26 (5) | 0.026 |
| Grade 2 (2.5- ≥5 X ULN) | 10 (2) | 2 (0.4) | 0.020 |
| CD4 count (cells per μL) | 449 (IQR 320–642) | - | - |
| Nadir CD4 count (cells per μL) | 214 (130–350) | - | - |
| Receiving ART | 302 (60) | - | - |
| ART duration (months) | 19 (9–38) | - | - |
BMI=body mass index, TB=tuberculosis, HBsAg= hepatitis B surface antigen, Anti-HBc=antibody to hepatitis B core, ALT= alanine transaminase, AST= aspartate transaminase, ACTG= AIDS Clinical Trial Group, ART=antiretroviral therapy, ULN= upper limit of normal (Female 39.9 U/L, Male 43.3 U/L).
*
Data are n (%) or median (IQR).